136 related articles for article (PubMed ID: 3517243)
1. A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma.
Wiltshaw E; Evans B; Rustin G; Gilbey E; Baker J; Barker G
J Clin Oncol; 1986 May; 4(5):722-9. PubMed ID: 3517243
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial.
Williams CJ; Mead GM; Macbeth FR; Thompson J; Whitehouse JM; MacDonald H; Harvey VJ; Slevin ML; Lister TA; Shepherd JH
J Clin Oncol; 1985 Nov; 3(11):1455-62. PubMed ID: 3903062
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy of advanced ovarian adenocarcinoma: a randomized comparison of combination versus sequential therapy using chlorambucil and cisplatin.
Gynecol Oncol; 1986 Jan; 23(1):1-13. PubMed ID: 3510944
[TBL] [Abstract][Full Text] [Related]
5. Randomised trial comparing low-dose cisplatin and chlorambucil with low-dose cisplatin, chlorambucil, and doxorubicin in advanced ovarian carcinoma.
Barker GH; Wiltshaw E
Lancet; 1981 Apr; 1(8223):747-50. PubMed ID: 6110955
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.
Lévi F; Benavides M; Chevelle C; Le Saunier F; Bailleul F; Misset JL; Regensberg C; Vannetzel JM; Reinberg A; Mathé G
J Clin Oncol; 1990 Apr; 8(4):705-14. PubMed ID: 2179481
[TBL] [Abstract][Full Text] [Related]
8. [Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer].
Sevelda P; Kurz C; Obermair A; Vavra N; Breitenecker G; Czerwenka K; Dittrich C; Salzer H
Wien Klin Wochenschr; 1993; 105(24):732-6. PubMed ID: 8116312
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
[TBL] [Abstract][Full Text] [Related]
10. Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer.
Rothenberg ML; Ozols RF; Glatstein E; Steinberg SM; Reed E; Young RC
J Clin Oncol; 1992 May; 10(5):727-34. PubMed ID: 1569445
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival with advanced ovarian cancer: an analysis of 5-year survivors in the Australian trial comparing combination versus sequential chlorambucil and cisplatin therapy.
Tattersall MH; Swanson CE; Solomon HJ
Gynecol Oncol; 1992 Dec; 47(3):292-7. PubMed ID: 1473740
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer.
Kohn EC; Sarosy GA; Davis P; Christian M; Link CE; Ognibene FP; Sindelar WF; Jacob J; Steinberg SM; Premkumar A; Reed E
Gynecol Oncol; 1996 Aug; 62(2):181-91. PubMed ID: 8751547
[TBL] [Abstract][Full Text] [Related]
13. Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin.
Pater JL; Carmichael JA; Krepart GV; Fraser RC; Roy M; Kirk ME; Levitt M; Brown LB; Wilson KS; Shelley WE
Cancer Treat Rep; 1987 Mar; 71(3):277-81. PubMed ID: 3102056
[TBL] [Abstract][Full Text] [Related]
14. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA
J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
[TBL] [Abstract][Full Text] [Related]
15. [Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients].
Salzer H; Gitsch E; Dittrich C; Sevelda P; Karrer K; Schemper M; Stempel-Smekal G; Langer M; Wagner G; Rainer H
Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):761-8. PubMed ID: 3908214
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin, adriamycin and cyclophosphamide (PACe) combination chemotherapy in patients with ovarian carcinoma resistant to chlorambucil.
Mead GM; Williams CJ; Whitehouse JM
Cancer Chemother Pharmacol; 1985; 15(2):179-80. PubMed ID: 3839443
[TBL] [Abstract][Full Text] [Related]
17. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.
McGuire WP; Hoskins WJ; Brady MF; Homesley HD; Creasman WT; Berman ML; Ball H; Berek JS; Woodward J
J Clin Oncol; 1995 Jul; 13(7):1589-99. PubMed ID: 7602348
[TBL] [Abstract][Full Text] [Related]
18. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.
Alberts DS; Green S; Hannigan EV; O'Toole R; Stock-Novack D; Anderson P; Surwit EA; Malvlya VK; Nahhas WA; Jolles CJ
J Clin Oncol; 1992 May; 10(5):706-17. PubMed ID: 1569443
[TBL] [Abstract][Full Text] [Related]
19. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer.
De Placido S; Tramontana S; Ferrari E; De Matteis A; Lauria R; Perrone F; Bianco AR; Gallo C; Ricchi P; De Placido G; Pignata S;
Anticancer Res; 2000; 20(5C):4023-9. PubMed ID: 11268496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]